Nabriva Therapeutics: ZIT Grant received for Extended Spectrum Pleuromutilin (ESP) Program

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for serious infections caused by resistant pathogens, announced the receipt of an R&D grant from the ZIT (Technology Agency of the City of Vienna).

In the course of the ZIT call "From Science to Products 2013" Nabriva received funds for its in-house Extended Spectrum Pleuromutilins program (ESP). ESP extend the conventional spectrum of known pleuromutilins by important Gram-negative bacteria, addressing a significant unmet medical need. The ZIT grant supports the optimization of novel ESP candidates so that they can be administered by both intravenous and oral route allowing significant reduction in overall treatment costs.

"This grant is a substantial contribution to the further development of our pipeline. It shows that our ESP program has been recognized for its strong potential to develop a new class of antibacterials  that addresses the need for new treatment options in an area facing growing resistance against all established antibiotics.", stated Ralf Schmid, Nabriva´s CEO.

For further information about ZIT, please visit:

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)